{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:17:40Z","timestamp":1785507460392,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40119-025-00402-y","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T17:15:41Z","timestamp":1742404541000},"page":"477-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6174-9232","authenticated-orcid":false,"given":"Julian D.","family":"Gillmore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Gustav","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Concei\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Pao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wittbrodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"J\u00e4rbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia A.","family":"Papas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot K.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"1","key":"402_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-021-01706-7","volume":"16","author":"D Rintell","year":"2021","unstructured":"Rintell D, Heath D, Braga Mendendez F, et al. Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups. Orphanet J Rare Dis. 2021;16(1):70.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"402_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","volume":"27","author":"J Nativi-Nicolau","year":"2022","unstructured":"Nativi-Nicolau J, Karam C, Khella S, Maurer M. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785\u201393.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"402_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Concei\u00e7\u00e3o","year":"2016","unstructured":"Concei\u00e7\u00e3o I, Gonz\u00e1lez-Duarte A, Obici L, et al. \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5\u20139.","journal-title":"J Peripher Nerv Syst"},{"issue":"29","key":"402_CR4","doi-asserted-by":"publisher","first-page":"27207","DOI":"10.1074\/jbc.M101024200","volume":"276","author":"A Quintas","year":"2001","unstructured":"Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem. 2001;276(29):27207\u201313.","journal-title":"J Biol Chem"},{"issue":"7","key":"402_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520\u20138.","journal-title":"Eur Heart J"},{"key":"402_CR6","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijcard.2018.06.006","volume":"270","author":"L Mohamed-Salem","year":"2018","unstructured":"Mohamed-Salem L, Santos-Mateo JJ, Sanchez-Serna J, et al. Prevalence of wild-type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2018;270:192\u20136.","journal-title":"Int J Cardiol"},{"issue":"6","key":"402_CR7","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s12350-020-02152-x","volume":"28","author":"C Cuscaden","year":"2021","unstructured":"Cuscaden C, Ramsay SC, Prasad S, Goodwin B, Smith J. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. J Nucl Cardiol. 2021;28(6):2845\u201356.","journal-title":"J Nucl Cardiol"},{"issue":"8","key":"402_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","volume":"47","author":"PN Hawkins","year":"2015","unstructured":"Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625\u201338.","journal-title":"Ann Med"},{"issue":"5","key":"402_CR9","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","volume":"88","author":"A Cortese","year":"2017","unstructured":"Cortese A, Vegezzi E, Lozza A, et al. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry. 2017;88(5):457\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"402_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40120-020-00183-7","volume":"9","author":"A Gonzalez-Duarte","year":"2020","unstructured":"Gonzalez-Duarte A, Conceicao I, Amass L, Botteman MF, Carter JA, Stewart M. Impact of non-cardiac clinicopathologic characteristics on survival in transthyretin amyloid polyneuropathy. Neurol Ther. 2020;9(1):135\u201349.","journal-title":"Neurol Ther"},{"issue":"1","key":"402_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB. THAOS\u2014the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"402_CR12","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"C Writing","year":"2023","unstructured":"Writing C, Kittleson MM, Ruberg FL, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076\u2013126.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"402_CR13","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"key":"402_CR14","unstructured":"CADTH Common Drug Reviews. CADTH Canadian Drug Expert Committee recommendation: tafamidis meglumine (Vyndaqel \u2013 Pfizer Canada ULC): Indication: for the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis, wild-type or hereditary, Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Copyright \u00a9 2020 Canadian Agency for Drugs and Technologies in Health. 2020."},{"key":"402_CR15","unstructured":"European Medicines Agency. Vyndaqel : EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyndaqel-epar-product-information_en.pdf. Accessed 13 September, 2024."},{"key":"402_CR16","unstructured":"US Food and Drug Administration. FDA approves drug for heart disorder caused by transthyretin-mediated amyloidosis. 2024. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-heart-disorder-caused-transthyretin-mediated-amyloidosis. Accessed 13 Sept 2024."},{"key":"402_CR17","unstructured":"Bayer. Heart drug Beyonttra\u2122 (acoramidis) approved in EU for treatment of transthyretin amyloidosis in adults with cardiomyopathy. 2015."},{"issue":"2","key":"402_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342.","journal-title":"N Engl J Med"},{"issue":"15","key":"402_CR19","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2023.15087","volume":"330","author":"A Gonzalez-Duarte","year":"2023","unstructured":"Gonzalez-Duarte A. Novel treatments for hereditary ATTRv amyloidosis. JAMA. 2023;330(15):1433\u20134.","journal-title":"JAMA"},{"issue":"3","key":"402_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mus.28026","volume":"69","author":"C Karam","year":"2024","unstructured":"Karam C, Mauermann ML, Gonzalez-Duarte A, et al. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: recommendations from a panel of experts. Muscle Nerve. 2024;69(3):273\u201387.","journal-title":"Muscle Nerve"},{"key":"402_CR21","unstructured":"European Medicines Agency. Onpattro : EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/onpattro-epar-product-information_en.pdf. Accessed 13 September, 2024."},{"key":"402_CR22","unstructured":"European Medicines Agency. Amvuttra : EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/amvuttra-epar-product-information_en.pdf. Accessed 13 September, 2024."},{"key":"402_CR23","unstructured":"European Medicines Agency. Tegsedi : EPAR - Product Information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tegsedi-epar-product-information_en.pdf. Accessed 13 September, 2024."},{"issue":"1","key":"402_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"402_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","volume":"27","author":"L Obici","year":"2020","unstructured":"Obici L, Berk JL, Gonzalez-Duarte A, et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2020;27(3):153\u201362.","journal-title":"Amyloid"},{"issue":"15","key":"402_CR26","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho T, Marques W Jr, Dasgupta NR, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy. JAMA. 2023;330(15):1448\u201358.","journal-title":"JAMA"},{"issue":"4","key":"402_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139(4):431\u201343.","journal-title":"Circulation"},{"issue":"17","key":"402_CR28","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389(17):1553\u201365.","journal-title":"N Engl J Med"},{"issue":"2","key":"402_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ejhf.3138","volume":"26","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Grogan M, Kale P, et al. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail. 2024;26(2):397\u2013410.","journal-title":"Eur J Heart Fail"},{"key":"402_CR30","unstructured":"Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl J Med. 2024."},{"issue":"4","key":"402_CR31","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","volume":"3","author":"JM Griffin","year":"2021","unstructured":"Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR amyloidosis: current and emerging management strategies: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2021;3(4):488\u2013505.","journal-title":"JACC CardioOncol"},{"key":"402_CR32","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1007\/s13311-021-01154-y","volume":"18","author":"L Obici","year":"2021","unstructured":"Obici L, Mussinelli R. Current and emerging therapies for hereditary transthyretin amyloidosis: strides towards a brighter future. Neurotherapeutics. 2021;18:2286\u2013302.","journal-title":"Neurotherapeutics"},{"issue":"7 Suppl","key":"402_CR33","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 Suppl):S107\u201312.","journal-title":"Am J Manag Care"},{"issue":"1","key":"402_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1185\/03007995.2012.754349","volume":"29","author":"V Plante-Bordeneuve","year":"2013","unstructured":"Plante-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin. 2013;29(1):77\u201384.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"402_CR35","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","volume":"18","author":"L Gentile","year":"2023","unstructured":"Gentile L, Coelho T, Dispenzeri A, et al. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Orphanet J Rare Dis. 2023;18(1):350.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"402_CR36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/13506129.2023.2229484","volume":"30","author":"T Coelho","year":"2023","unstructured":"Coelho T, Dispenzieri A, Grogan M, et al. Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay. Amyloid. 2023;30(4):445\u20138.","journal-title":"Amyloid"},{"key":"402_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2024.06.003","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia P, Kristen AV, Drachman B, et al. Survival in a real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). J Card Fail. 2024. https:\/\/doi.org\/10.1016\/j.cardfail.2024.06.003.","journal-title":"J Card Fail."},{"issue":"1","key":"402_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40120-018-0097-9","volume":"7","author":"R Mundayat","year":"2018","unstructured":"Mundayat R, Stewart M, Alvir J, et al. Positive effectiveness of tafamidis in delaying disease progression in transthyretin familial amyloid polyneuropathy up to 2 years: an analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Neurol Ther. 2018;7(1):87\u2013101.","journal-title":"Neurol Ther"}],"updated-by":[{"DOI":"10.1007\/s40119-025-00417-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000}}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00402-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00402-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00402-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:53:24Z","timestamp":1757145204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00402-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00402-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40119-025-00417-5","asserted-by":"object"}]},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40119-025-00417-5","URL":"https:\/\/doi.org\/10.1007\/s40119-025-00417-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Julian D. Gillmore has acted as an advisor for Alnylam, AstraZeneca, Attralus, BridgeBio, Intellia, Ionis Pharmaceuticals, Inc., and Pfizer. Katrin Hahn has received consulting or speaking honoraria from Akcea, Alnylam, Amicus, AstraZeneca, GSK, Hormosan, Takeda, Pfizer, Swedish Orphan Biovitrum, and ViiV Healthcare, research funding from the foundation Charit\u00e9 (Berlin Institute of Health clinical fellow), Alnylam, and Pfizer, and financial reimbursement for educational activities from the German Society of Neurology. J. Gustav Smith reports that his employer (Gothenburg University) is paid by AstraZeneca for his involvement in ANTHOLOGY (no personal payment). Isabel Concei\u00e7\u00e3o has acted as an advisor for Alnylam, AstraZeneca, BridgeBio, Intellia, Ionis Pharmaceuticals, Inc., and Pfizer, and acknowledges financial support as a primary investigator from Pfizer, Alnylam, and Ionis Pharmaceuticals, Inc. Zhuang Tian has no competing interests to declare. Martha Grogan has received research funding from Alnylam, Eidos, Janssen, Novo Nordisk, and Pfizer, and consulting or speaking honoraria from Alnylam, AstraZeneca, BridgeBio, Janssen, and Novo Nordisk. Christina Pao was an employee and shareholder of AstraZeneca at the time of submission. Eric Wittbrodt, Krister J\u00e4rbrink, and Mia A. Papas are employees of, and hold stock in, AstraZeneca. Margot K. Davis has received consulting or speaking honoraria from AstraZeneca, Ionis Pharmaceuticals, Inc., Novo Nordisk, Bayer, Janssen, Ferring, Pfizer, Alnylam, Anthos, Boehringer Ingelheim\/Lilly, and Jazz Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Both observational studies will adhere to ethical principles that are consistent with the 1964 Declaration of Helsinki and its later amendments, Good Clinical Practices (GCP) guidelines of the International Conference on Harmonization (ICH), Guidelines for Good Pharmacoepidemiology Practices (GPP), and applicable legislation on non-interventional and\/or observational studies. The investigators will perform their duties in adherence to local regulations and guidelines governing medical practice and ethics. Local ethics approvals will be obtained for data use where necessary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}